Showing results (1-10 of 102) with videos related to
Sort By:
Pageof 11
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2009
MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetanDarrell R Fisher, Sui Shen, Ruby F MeredithJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2008
A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebraeRuby F Meredith, Sui Shen, Andres Forero, et al.Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.International Journal of Radiation Oncology, Biology, Physics|September 19, 2006
Logistics of therapy with the ibritumomab tiuxetan regimenRuby F MeredithInternational Journal of Radiation Oncology, Biology, Physics|September 19, 2006
Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphomaRuby F MeredithJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2002
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.Cancer|March 6, 2002
Model prediction of treatment planning for dose-fractionated radioimmunotherapySui Shen, Jun Duan, Ruby F Meredith, et al.Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.Pageof 11